theodore huizenga  ultragenyx pharmaceutical inc  zoominfocom ultragenyx pharmaceutical inc rare rating increased to hold at valuengine  american banking news home get email updates about disclaimer contact privacy policy   business news us news world news stock ratings analysts upgrades analysts downgrades analysts eps estimates analysts price targets analysts new coverage corporate earnings earnings results earnings guidance earnings previews dividends insider trades options press releases ultragenyx pharmaceutical inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for ultragenyx pharmaceutical inc with our free daily email newsletter recent stories total system services inc nysetss releases fy earnings guidance trinity industries inc trn releases fy earnings guidance express scripts holding company esrx issues q earnings guidance eastgroup properties inc egp issues fy earnings guidance express scripts holding company nasdaqesrx updates fy earnings guidance smart nysesfs issues fy earnings guidance celestica inc nysecls issues q earnings guidance farmers capital bank corporation nasdaqffkt lifted to “strongbuy” at zacks investment research goodrich petroleum corp gdp downgraded to sell at zacks investment research first community corporation nasdaqfcco cut to “sell” at zacks investment research zacks investment research lowers floor  decor holdings inc nysefnd to hold energy transfer equity lp ete stock rating lowered by zacks investment research global partners lp nyseglp raised to strongbuy at zacks investment research zacks investment research upgrades glu mobile inc gluu to hold exa corporation nasdaqexa downgraded by zacks investment research to hold fulton financial corporation nasdaqfult stock rating upgraded by zacks investment research fortuna silver mines inc fsm rating increased to hold at zacks investment research st constitution bancorp nj fccy downgraded to strong sell at zacks investment research farmers  merchants bancorp inc fmao stock rating upgraded by zacks investment research experian plc expgy lifted to “hold” at zacks investment research ultragenyx pharmaceutical inc rare rating increased to hold at valuengine june th  •  comments • filed under • by abmn staff filed under analysts upgrades • market news tweet ultragenyx pharmaceutical inc nasdaqrare was upgraded by equities researchers at valuengine from a “sell” rating to a “hold” rating in a research note issued on thursday several other research firms have also commented on rare suntrust banks inc raised their price target on shares of ultragenyx pharmaceutical from  to  and gave the company a “buy” rating in a research report on wednesday april th canaccord genuity restated a “buy” rating and set a  price target on shares of ultragenyx pharmaceutical in a research report on thursday march rd robert w baird restated an “outperform” rating and set a  price target on shares of ultragenyx pharmaceutical in a research report on wednesday april th jefferies group llc lowered shares of ultragenyx pharmaceutical from a “buy” rating to a “hold” rating and dropped their price target for the company from  to  in a research report on thursday april th finally hc wainwright lowered shares of ultragenyx pharmaceutical from a “buy” rating to a “neutral” rating and dropped their price target for the company from  to  in a research report on wednesday april th one analyst has rated the stock with a sell rating eight have issued a hold rating and eight have assigned a buy rating to the company the stock has a consensus rating of “hold” and an average price target of  get ultragenyx pharmaceutical inc alerts ultragenyx pharmaceutical nasdaqrare traded up  on thursday hitting   shares of the company were exchanged the company’s market capitalization is  billion ultragenyx pharmaceutical has a  week low of  and a  week high of  the firm’s  day moving average is  and its  day moving average is  ultragenyx pharmaceutical nasdaqrare last released its quarterly earnings results on thursday may th the biopharmaceutical company reported  eps for the quarter beating the thomson reuters’ consensus estimate of  by  during the same quarter last year the business posted  eps on average equities research analysts forecast that ultragenyx pharmaceutical will post  earnings per share for the current fiscal year illegal activity warning this report was first posted by american banking news and is the property of of american banking news if you are accessing this report on another domain it was copied illegally and reposted in violation of us and international trademark and copyright laws the legal version of this report can be accessed at httpswwwamericanbankingnewscomultragenyxpharmaceuticalincrareratingincreasedtoholdatvaluenginehtml in other ultragenyx pharmaceutical news vp theodore alan huizenga sold  shares of the stock in a transaction on friday may th the shares were sold at an average price of  for a total transaction of  following the transaction the vice president now directly owns  shares of the company’s stock valued at  the transaction was disclosed in a legal filing with the sec which is accessible through the sec website company insiders own  of the company’s stock several institutional investors have recently bought and sold shares of rare fortaleza asset management inc increased its position in ultragenyx pharmaceutical by  in the first quarter fortaleza asset management inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares in the last quarter pacer advisors inc increased its position in ultragenyx pharmaceutical by  in the first quarter pacer advisors inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares in the last quarter strs ohio increased its position in ultragenyx pharmaceutical by  in the first quarter strs ohio now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares in the last quarter ameritas investment partners inc increased its position in ultragenyx pharmaceutical by  in the first quarter ameritas investment partners inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares in the last quarter finally massmutual trust co fsb adv acquired a new position in ultragenyx pharmaceutical during the first quarter valued at   of the stock is currently owned by hedge funds and other institutional investors ultragenyx pharmaceutical company profile ultragenyx pharmaceutical inc is a clinicalstage biopharmaceutical company the company is focused on the identification acquisition development and commercialization of products for the treatment of genetic diseases its clinicalstage pipeline consists of two product categories biologics including a monoclonal antibody and an enzyme replacement therapy and smallmolecule substrate replacement therapies to view valuengine’s full report visit valuengine’s official website receive news  ratings for ultragenyx pharmaceutical inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for ultragenyx pharmaceutical inc and related companies with marketbeatcoms free daily email newsletter leave a reply click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation  copyright american banking and market news  all rights reserved privacy policy and disclosures  about  advertising  contact content on this website is not meant to be a recommendation or an offer to buy or sell any security click here to read our full disclaimer   insider trading  huizenga theodore alan  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  huizenga theodore alan select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao    direct view salea  pm ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao    direct view sale  pm ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao    direct view sale  pm ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao    direct view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view option award  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view option award  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view tax withholding  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view option award  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view option award  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm nana ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view exercise  pm na ultragenyx pharmaceutical inc rare huizenga theodore alancontroller and pao   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft theodore alan huizenga  ultragenyx insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailstheodore alan huizengaultragenyx rarecontroller and paoranked  out of  insiders on tiprankstheodore alan huizengas performanceprofitable transactions out of  profitable transactionsaverage returnaverage return per transactioneach transaction is measured over a  year months month period and compared to no benchmarksp sectorhow are insiders ranked insider holdings  ultragenyx rareksee the top stocks by insiders  insider rolesultragenyx rare controller and paosee the top  corporate insiders  most profitable insider tradestock ultragenyx raretransaction type informative buydates mar    mar  gain see the latest stocks traded by insiders  theodore alan huizengas trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction daterareultragenyxcontroller and paoinformative sellmay  success rate on stock out of  profitable transactions on rareaverage profit on stockaverage return per transaction on rare  track record showingall transactionsinformative transactionsdatetransactionamountno of sharesprice per shareprofitform  may   informative sell k    may   uninformative sell k   na mar   informative sell k    show moresee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by sale by theodore huizenga of  shares of ultragenyx pharmaceutical  rare  macroaxis research hub sign in sign in new account about macroaxis settings plans  pricing toggle menu toggle fullscreen  markets equities portfolios stories × my equities investing ideas free tools world markets map cryptocurrency center equity research company directory insider directory buy or sell recommendation pair correlation stocks correlation pattern recognition watchlist analysis services technology overview solution methodology acknowledgement product tour faqs about us about macroaxis contact us terms of use privacy policy advertising        get advice nantkwestdel mardimension therapeuticsvbi vaccinesemil kakkiseran nadavjohn pinion world us ultragenyx pharmaceutical story equity search company directory suggest portfolio backtest watchlist analyze correlations view transactions check volatility import equities summary performance fundamentals technicals recommendation profile essentials valuation headlines leaders hype analysis diagnosticsdashboard upgrade to remove ads ultragenyx pharmaceutical inc  usa stock  usd      macroaxis does not monitor all media channels or aggregates social signals for ultragenyx pharmaceutical but even though we do not provide professionalgrade financial sentiment analysis on ultragenyx pharmaceutical we do publish noisefree headlines that can be used to derive useful patterns or even a trading strategy for ultragenyx pharmaceutical additionally take a look at ultragenyx pharmaceutical hype analysis ultragenyx pharmaceutical correlation and ultragenyx pharmaceutical performance sale by huizenga theodore alan of  shares of ultragenyx pharmaceuticalat macroaxiscommay  filed transaction by ultragenyx pharmaceutical officer general open market or private sale of nonderivative or derivative securitypublished over two months agoview all stories for ultragenyx pharmaceutical  ultragenyx pharmaceutical hype analysisultragenyx pharmaceutical inc insider trading alert for sale of common stock by huizenga theodore alan vp controller and pao on may   this event was filed by ultragenyx pharmaceutical with sec on  statement of changes in beneficial ownership  sec form cash floor correlationcash beginning of yearcash end of yearcapital expenditureshare based compensationcash beginning of yearcash end of yearcapital expenditureshare based compensationclick cells to compare fundamentals   view all correlationsstory momentumthis media report from macroaxisinsider distributed on may   was a factor to the next trading day price decreasethe trading delta at closing time against the next closing price was   the trading price change when the story was published against the current closing price is   similar stores for ultragenyx pharmaceuticala day ago at httpwwwbaseballnewsblogcom ultragenyx pharmaceutical inc shares bought by amalgamated bankultragenyx pharmaceutical logo amalgamated bank increased its position in shares of ultragenyx pharmaceutical inc by  percent during the first quarter according to its most recent f filing with the securities and exchange commission  wall street stock recommendations ultragenyx pharmaceutical inc rare   post analyst is there inherent value in ultragenyx pharmaceutical inc  clayton newsmomentumview storyover two weeks ago at httpwwwthecerbatgemcom ultragenyx pharmaceutical inc  receive news and ratings dailyultragenyx pharmaceutical inc was downgraded by zacks investment research from a hold rating to a sell rating in a research report issued to clients and investors on tuesday ultragenyx pharmaceutical reaches  after  percent up move shorts at   utahheraldcom parametric portfolio associates llc acquires  shares of ultragenyx   bnb dailymomentumview storyover a month ago at httpevergreencallercom share activity lifted for ultragenyx pharmaceutical inc in sessionshares of ultragenyx pharmaceutical inc are moving on volatility today  percent or  from the open the nasdaq listed company saw a recent bid of  and  shares have traded hands in the sessionmomentumview story did you try thisrun pattern recognition now   pattern recognitionuse different pattern recognition models to time the market across multiple global exchangeshide  view all  next  launch pattern recognitionmarket capitalizationmarket capitalization comparative analysis  market capitalization       ultragenyx pharmaceutical comparables ultragenyx pharmaceutical is currently under evaluation in market capitalization category among related companies market capitalization is total market value of a companys equity it is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued if a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares however if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of sharesmorepeersyour trending equities s         sprint profile sprint dashboard sprint technical analysis backtest sprint sprint news timeline sprint analyst consensus sprint fundamentals trends aa         alcoa profile alcoa dashboard alcoa technical analysis backtest alcoa alcoa news timeline alcoa analyst consensus alcoa fundamentals trends aapl         apple profile apple dashboard apple technical analysis backtest apple apple news timeline apple analyst consensus apple fundamentals trends aal         american airlines profile american airlines dashboard american airlines technical analysis backtest american airlines american airlines news timeline american airlines analyst consensus american airlines fundamentals trends paa         plains all profile plains all dashboard plains all technical analysis backtest plains all plains all news timeline plains all analyst consensus plains all fundamentals trends c         citigroup profile citigroup dashboard citigroup technical analysis backtest citigroup citigroup news timeline citigroup analyst consensus citigroup fundamentals trends chep         quantshares us profile quantshares us dashboard quantshares us technical analysis backtest quantshares us quantshares us news timeline wtrx         elevation etf profile elevation etf dashboard elevation etf technical analysis backtest elevation etf elevation etf news timeline hy         hyster yale profile hyster yale dashboard hyster yale technical analysis backtest hyster yale hyster yale news timeline hyster yale analyst consensus hyster yale fundamentals trends xcapx         acap strategic profile acap strategic dashboard acap strategic technical analysis backtest acap strategic cvs         cvs health profile cvs health dashboard cvs health technical analysis backtest cvs health cvs health news timeline cvs health analyst consensus cvs health fundamentals trends cvx         chevron profile chevron dashboard chevron technical analysis backtest chevron chevron news timeline chevron analyst consensus chevron fundamentals trends epe         ep energy profile ep energy dashboard ep energy technical analysis backtest ep energy ep energy news timeline ep energy analyst consensus ep energy fundamentals trends bby         best buy profile best buy dashboard best buy technical analysis backtest best buy best buy news timeline best buy analyst consensus best buy fundamentals trends abax         abaxis profile abaxis dashboard abaxis technical analysis backtest abaxis abaxis news timeline abaxis analyst consensus abaxis fundamentals trends updating transaction report was successfully generated   macroaxis llc all rights reserved   insiders companies contact us feedback widgets ultragenyx pharmaceutical nasdaqrare news  analysis ultragenyx pharmaceutical company profile nasdaqrare company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about ultragenyx pharmaceutical nasdaqrare ultragenyx pharmaceutical inc is a clinicalstage biopharmaceutical company the company is focused on the identification acquisition development and commercialization of products for the treatment of genetic diseases its clinicalstage pipeline consists of two product categories biologics including a monoclonal antibody and an enzyme replacement therapy and smallmolecule substrate replacement therapies its product candidates under biologics category include krn ux and recombinant human betaglucuronidase rhgus ux its product candidates under smallmolecule category include ux and aceneuramic acid extendedrelease aceer ux it is also developing recombinant human protective protein cathepsina rhppca krn is a fully human monoclonal antibody rhgus is an intravenous iv enzyme replacement therapy ux is a substrate replacement therapy it is developing aceer for the treatment of gne myopathy rhppca is in preclinical development industry sector and symbol sector medical industry bio therapeutic drugs subindustry na symbol nasdaqrare cusip na web wwwultragenyxcom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue price  sales book value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for ultragenyx pharmaceutical nasdaqrare what is ultragenyx pharmaceuticals stock symbol ultragenyx pharmaceutical trades on the nasdaq under the ticker symbol rare how were ultragenyx pharmaceuticals earnings last quarter ultragenyx pharmaceutical inc nasdaqrare released its quarterly earnings data on thursday july th the company reported  earnings per share for the quarter topping the zacks consensus estimate of  by  during the same quarter last year the business posted  earnings per share view ultragenyx pharmaceuticals earnings history where is ultragenyx pharmaceuticals stock going where will ultragenyx pharmaceuticals stock price be in   brokerages have issued twelvemonth target prices for ultragenyx pharmaceuticals stock their predictions range from  to  on average they anticipate ultragenyx pharmaceuticals share price to reach  in the next year view analyst ratings for ultragenyx pharmaceutical what are analysts saying about ultragenyx pharmaceutical stock here are some recent quotes from research analysts about ultragenyx pharmaceutical stock  according to zacks investment research ultragenyx pharmaceutical inc is involved in the identification acquisition development and commercialization of products for the treatment of rare and ultrarare diseases with an initial focus on serious debilitating metabolic genetic diseases the companys product pipeline include krn ux for the treatment of xlh rhgus ux for the treatment of mps  rhppca ux for the treatment of galactosialidosis triheptanoin ux for the treatment of lcfaod triheptanoin ux for the treatment of glut ds and saer ux for the treatment of hibm which are in different clinical phases ultragenyx pharmaceutical inc is headquartered in novato california    cowen and company analysts commented we continue to see pacira’s exparel franchise as one of the most durable in specialty pharma and we believe that over time exparel will continue to gain acceptance in the ortho community   canaccord genuity analysts commented insm’s ph arikayce ntm convert trial data is due september of this year   jefferies group llc analysts commented uneventful  fourth quarter earnings call as the company is expecting first commercial product by the end of wang comments rare q ec was largely uneventful mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by ye we see overall favorable riskreward heading into multiple data and regulatory catalysts in  including krn ph data in adult xlh h bla filing in the us chmp opinion in eu h aceer ph data in gne myopathy h rare reported q opex of m vs ourconsensus est of m eps was  vs ourconsensus est of  the company ended the quarter with m cash and guided that the cash should be sufficient to fund all clinical programs through ph studies and potential launch mgmt guided to a continual increase in opex with a gradually slower yoy growth our  target is based on probability adjusted dcf risks include delay in eu conditional approval less robust data toxicity  who are some of ultragenyx pharmaceuticals key competitors some companies that are related to ultragenyx pharmaceutical include clovis oncology clvs neurocrine biosciences nbix bluebird bio blue intercept pharmaceuticals icpt juno therapeutics juno gw pharmaceuticals plc gwph beigene bgne agios pharmaceuticals agio china biologic products cbpo avexis avxs axovant sciences axon prothena corporation plc prta sarepta therapeutics srpt spark therapeutics once loxo oncology loxo aerie pharmaceuticals aeri radius health rdus and novocure limited nvcr who are ultragenyx pharmaceuticals key executives ultragenyx pharmaceuticals management team includes the folowing people daniel g welch independent chairman of the boardemil d kakkis md phd president chief executive officer directorshalini sharp chief financial officer executive vice presidentsunil agarwal md president  research and developmentkarah parschauer executive vice president general counseljayson dallas md chief commercial officer and executive vice presidentdennis karl huang chief technical operations officer executive vice presidentthomas kassberg chief business officer executive vice presidentjohn r pinion ii chief quality operations officer and executive vice president analytical sciences and researchwilliam e aliski independent director who owns ultragenyx pharmaceutical stock ultragenyx pharmaceuticals stock is owned by a variety of of institutional and retail investors top institutional shareholders include rockefeller financial services inc  russell investments group ltd  rothschild asset management inc  state of new jersey common pension fund d  bank of montreal can  and public employees retirement association of colorado  company insiders that own ultragenyx pharmaceutical stock include emil d kakkis shalini sharp sunil agarwal theodore alan huizenga thomas richard kassberg and william aliski view institutional ownership trends for ultragenyx pharmaceutical who sold ultragenyx pharmaceutical stock who is selling ultragenyx pharmaceutical stock ultragenyx pharmaceuticals stock was sold by a variety of institutional investors in the last quarter including bank of montreal can and rothschild asset management inc company insiders that have sold ultragenyx pharmaceutical stock in the last year include emil d kakkis shalini sharp theodore alan huizenga and william aliski view insider buying and selling for ultragenyx pharmaceutical who bought ultragenyx pharmaceutical stock who is buying ultragenyx pharmaceutical stock ultragenyx pharmaceuticals stock was acquired by a variety of institutional investors in the last quarter including rockefeller financial services inc russell investments group ltd and aperio group llc view insider buying and selling for ultragenyx pharmaceutical how do i buy ultragenyx pharmaceutical stock shares of ultragenyx pharmaceutical can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is ultragenyx pharmaceuticals stock price today one share of ultragenyx pharmaceutical stock can currently be purchased for approximately  marketbeat community rating for ultragenyx pharmaceutical nasdaq rarecommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about ultragenyx pharmaceutical and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for ultragenyx pharmaceutical nasdaqrare how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  sell rating  hold ratings  buy ratingsconsensus ratinghold score consensus price target   upside analysts ratings history for ultragenyx pharmaceutical nasdaqrare show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailscanaccord genuityset price targetbuylowsanford c bernsteininitiated coveragemarket performhighjefferies group llcreiterated ratingholdhighstifel nicolausreiterated ratingbuylowcowen and companyreiterated ratingoutperformlowmorgan stanleylower price targetequal weight  lowrobert w bairdreiterated ratingoutperformmediumsuntrust banks incboost price targetbuy  mediumwedbushdowngradeoutperform  neutral  highhc wainwrightdowngradebuy  neutral  highpiper jaffray companiesreiterated ratingoverweight  neutralhighcitigroup incdowngradeneutral  sellnaleerink swannreiterated ratingoutperform  naj p morgan chase  coreiterated ratingbuynacredit suisse groupreiterated ratingbuynabank of america corporationinitiated coveragebuynajmp securitiesreiterated ratingbuy  nasterne agee crtinitiated coveragebuynaraymond james financial incinitiated coverageoutperformnadata available from  forward earnings earnings history for ultragenyx pharmaceutical nasdaqrareearnings history by quarter for ultragenyx pharmaceutical nasdaq raredatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsq  millionviewnaq  millionviewlistenq  million millionviewnaq million millionviewlistenq millionviewnaqviewnaqviewlistenqviewnaqviewlistenq viewlistenqviewlistenqviewnaqviewnaqviewnaviewnadata available from  forward estimates earnings estimates for ultragenyx pharmaceutical nasdaqrare eps consensus estimate  eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q q q q data provided by zacks investment research dividends dividend history for ultragenyx pharmaceutical nasdaqrareno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for ultragenyx pharmaceutical nasdaqrareinsider ownership percentage institutional ownership percentage insider trades by quarter for ultragenyx pharmaceutical nasdaqraretransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailstheodore alan huizengavpsell  theodore alan huizengainsidersell  shalini sharpcfosell  shalini sharpcfosell  william aliskidirectorsell  shalini sharpcfosell  shalini sharpcfosell  emil d kakkisceosell  emil d kakkisceosell  sunil agarwalinsidersell  emil d kakkisceosell  sunil agarwalinsidersell  sunil agarwalinsidersell  emil d kakkisceosell  sunil agarwalinsidersell  emil d kakkisceosell  sunil agarwalinsidersell  sunil agarwalinsidersell  sunil agarwalinsidersell  emil d kakkisceosell  sunil agarwalinsidersell  theodore alan huizengainsidersell  sunil agarwalinsidersell  thomas richard kassbergsvpsell  shalini sharpcfosell  thomas richard kassbergsvpsell  shalini sharpcfosell  theodore alan huizengainsidersell  thomas richard kassbergsvpsell  shalini sharpcfosell  thomas richard kassbergsvpsell  shalini sharpcfosell  shalini sharpcfosell  thomas richard kassbergsvpsell  william aliskidirectorsell  shalini sharpcfosell  thomas richard kassbergsvpsell  thomas richard kassbergsvpsell  shalini sharpcfosell  thomas richard kassbergsvpsell  thomas richard kassbergsvpsell  shalini sharpcfosell  group holdings sbs advis tpginsidersell  fmr llcinsiderbuy  shalini sharpcfobuy  thomas richard kassbergsvpbuy  william aliskidirectorbuy  data available from  forward headlines headline trends for ultragenyx pharmaceutical nasdaqrare latest headlines for ultragenyx pharmaceutical nasdaqrare source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlineultragenyx pharmaceutical inc nasdaqrare given a  price target at canaccord genuitywwwamericanbankingnewscom  july  at  pmagrx at fda altar again azn falls as mystic fails vbiv delivers a good shotwwwrttnewscom  july  at  amultragenyx an interesting company in the rare disease spaceseekingalphacom  july  at  amultragenyx reports second quarter  financial results and corporate updatefinanceyahoocom  july  at  amultragenyx reports q lossfinanceyahoocom  july  at  amedited transcript of rare earnings conference call or presentation jul pm gmtfinanceyahoocom  july  at  amultragenyx pharmaceutical inc nasdaqrare issues quarterly earnings resultswwwamericanbankingnewscom  july  at  pmultragenyx more than meets the eye  seeking alphaseekingalphacom  july  at  amglobal genes announces rare champions of hope award recipients to be honored at th annual rare tribute   pr newswire press releasewwwprnewswirecom  july  at  pmultragenyx poised to perform well on multiple catalystsseekingalphacom  july  at  amultragenyx pharmaceutical inc rare stock rating upgraded by zacks investment researchwwwamericanbankingnewscom  july  at  amultragenyx pharmaceutical rare shares cross above  dma  nasdaqwwwnasdaqcom  july  at  am in sales expected for ultragenyx pharmaceutical inc rare this quarterwwwamericanbankingnewscom  july  at  amultragenyx pharmaceutical inc nasdaqrare given hold rating at jefferies group llcwwwamericanbankingnewscom  july  at  pmzacks analysts anticipate ultragenyx pharmaceutical inc nasdaqrare will post earnings of  per sharewwwamericanbankingnewscom  july  at  pmultragenyx pharmaceutical inc rare stock rating lowered by zacks investment researchwwwamericanbankingnewscom  july  at  amultragenyx pharmaceutical inc nasdaqrare receives consensus rating of hold from analystswwwamericanbankingnewscom  july  at  amultragenyx pharmaceutical inc nasdaqrare rating reiterated by stifel nicolauswwwamericanbankingnewscom  june  at  pmultragenyx pharmaceutical inc rare earns buy rating from cowen and companywwwamericanbankingnewscom  june  at  pmultragenyx pharma rare provides regulatory update on burosumab following meeting with fdawwwstreetinsidercom  june  at  amultragenyx pharmaceutical inc rare rating increased to hold at valuenginewwwamericanbankingnewscom  june  at  pmultragenyx pharma rare provides regulatory update on burosumab following meeting with fda  streetinsidercomwwwstreetinsidercom  june  at  amultragenyx provides regulatory update on burosumab krnfinanceyahoocom  june  at  amultragenyx pharmaceutical inc rare expected to post quarterly sales of wwwamericanbankingnewscom  june  at  amzacks brokerages expect ultragenyx pharmaceutical inc rare will announce quarterly sales of wwwamericanbankingnewscom  june  at  amoh baby how expanded newborn screening could change the face of health carefinanceyahoocom  june  at  amultragenyx pharmaceutical inc rare upgraded by bidaskclub to holdwwwamericanbankingnewscom  june  at  pm brokerages anticipate ultragenyx pharmaceutical inc rare will post earnings of  per sharewwwamericanbankingnewscom  june  at  pmultragenyx pharmaceutical inc – value analysis nasdaqrare  june  financeyahoocom  june  at  pmultragenyx pharmaceutical inc rare receives consensus rating of hold from analystswwwamericanbankingnewscom  june  at  amultragenyx pharmaceutical inc breached its  day moving average in a bullish manner  rareus  june  financeyahoocom  june  at  pmultragenyx to present at goldman sachs th annual global healthcare conference  globenewswire press releaseglobenewswirecom  june  at  amultragenyx to present at goldman sachs th annual global healthcare conferencefinanceyahoocom  june  at  pmultragenyx pharmaceutical inc rarefinanceyahoocom  june  at  pmvaluengine upgrades ultragenyx pharmaceutical inc rare to sellwwwamericanbankingnewscom  june  at  pmultragenyx to present at jefferies global healthcare conferencefinanceyahoocom  june  at  pmultragenyx pharmaceutical inc rare vp theodore alan huizenga sells  shareswwwamericanbankingnewscom  may  at  pmzacks brokerages anticipate ultragenyx pharmaceutical inc rare to post  earnings per sharewwwamericanbankingnewscom  may  at  amultragenyx announces recombinant human betaglucuronidase biologics license globenewswirecom  may  at  amultragenyx pharma rare says recombinant human betaglucuronidase bla and maa filed and accepted for review fda grants priority review statuswwwstreetinsidercom  may  at  amultragenyx announces recombinant human betaglucuronidase biologics license application and marketing authorization application filed and accepted for review fda grants priority review statusfinanceyahoocom  may  at  amultragenyx pharmaceutical inc rare receives consensus rating of buy from brokerageswwwamericanbankingnewscom  may  at  amnewman ferrara llp announces corporate governance investigation of ultragenyx pharmaceutical inc  business wire press releasewwwbusinesswirecom  may  at  amnewman ferrara llp announces corporate governance investigation of ultragenyx pharmaceutical incfinanceyahoocom  may  at  amultragenyx to present at bank of america merrill lynch healthcare conferencefinanceyahoocom  may  at  pmultragenyx pharmaceutical inc rare receives buy rating from citigroup incwwwamericanbankingnewscom  may  at  pmultragenyx pharmaceutical inc rare expected to post q  earnings of  per sharewwwamericanbankingnewscom  may  at  amultragenyx to present at bank of america merrill lynch healthcare conference  globenewswire press releaseglobenewswirecom  may  at  pmsuntrust banks comments on ultragenyx pharmaceutical incs q  earnings rarewwwamericanbankingnewscom  may  at  amsuntrust banks research analysts increase earnings estimates for ultragenyx pharmaceutical inc rarewwwamericanbankingnewscom  may  at  pm social chart ultragenyx pharmaceutical rare chart for friday july   this page was last updated on  by marketbeatcom staff